Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | rHSC-DIPGVax |
| Synonyms | |
| Therapy Description |
rHSC-DIPGVax is a peptide vaccine comprising 16 heat shock protein (HSP) neoepitopes associated with diffuse intrinsic pontine glioma and diffuse midline glioma, which potentially enhances cytotoxic T-lymphocyte (CTL) response against HSP neoepitope-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| rHSC-DIPGVax | rHSC-DIPGVax is a peptide vaccine comprising 16 heat shock protein (HSP) neoepitopes associated with diffuse intrinsic pontine glioma and diffuse midline glioma, which potentially enhances cytotoxic T-lymphocyte (CTL) response against HSP neoepitope-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04943848 | Phase I | rHSC-DIPGVax Balstilimab + rHSC-DIPGVax Balstilimab + rHSC-DIPGVax + Zalifrelimab | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | Recruiting | USA | 0 |